Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | ABL503 |
Trade Name | |
Synonyms | ABL-503|ABL 503 |
Drug Descriptions |
ABL503 is a bispecific antibody that targets both CD274 (PD-L1) and TNFRSF9 (4-1BB), leading to activation of TNFRSF9 (4-1BB) and decreased CD274 (PD-L1) signaling, potentially resulting in activation of an antitumor immune response and inhibition of tumor growth (PMID: 34230109). |
DrugClasses | PD-L1/PD-1 antibody 117 TNFRSF9 Antibody 30 |
CAS Registry Number | NA |
NCIT ID | C179637 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ABL503 | ABL503 | 0 | 1 |